TrimTAC1 is a TRIM21 -based PROTAC degrader targeting BRD4 , with a DC 50 of 0.649 nM. TrimTAC1 selectively degrades multimeric proteins, including those localized in biomolecular condensates, while exerting no effect on monomeric proteins in the dilute phase. This degradation effect can be blocked by Bortezomib ( HY-10227 ) or TAK-243 ( HY-100487 ). TrimTAC1 can be used in research related to pancreatic cancer and autoimmune diseases. (Pink: BRD4 ligand ( HY-13030 ); Blue: TRIM21 ligand ( HY-169356 ); Black: linker ( HY-W088456 )).
Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Pancreatic Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Epigenetic Reader Domain
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.